{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:49:55Z","timestamp":1792612195217,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["ZIA-DA000069"],"award-info":[{"award-number":["ZIA-DA000069"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020882","name":"American Foundry Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopsych.2025.11.021","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:04:55Z","timestamp":1764867895000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment"],"prefix":"10.1016","volume":"100","author":[{"given":"Marjorie R.","family":"Levinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Schoenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Manza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jordi Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2025.11.021_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","volume":"81","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/aps.2016.5","article-title":"Ketamine use in current clinical practice","volume":"37","author":"Gao","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.biopsych.2025.11.021_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jad.2023.04.141","article-title":"The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis","volume":"335","author":"Hietamies","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.021_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive\u2013compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): A review of the current literature","volume":"11","author":"Martinotti","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib10","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.biopsych.2024.09.008","article-title":"Ketamine and hydroxynorketamine as novel pharmacotherapies for the treatment of opioid use disorders","volume":"97","author":"Onisiforou","year":"2025","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.biopsych.2025.11.021_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2025.11.021_bib18","article-title":"Role of ketamine in the treatment of substance use disorders: A systematic review","volume":"175","author":"Janssen-Aguilar","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.biopsych.2025.11.021_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/00952990.2020.1808982","article-title":"Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study","volume":"47","author":"Azhari","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.biopsych.2025.11.021_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2025.11.021_bib22","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2025.11.021_bib23","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.11.021_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320916657","article-title":"Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers","volume":"10","author":"Matveychuk","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.conb.2014.12.004","article-title":"Antidepressant actions of ketamine: From molecular mechanisms to clinical practice","volume":"30","author":"Monteggia","year":"2015","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","article-title":"Molecular pharmacology and neurobiology of rapid-acting antidepressants","volume":"59","author":"Gould","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib29","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","article-title":"Mu Opioid receptor activation mediates (S)-ketamine reinforcement in rats: Implications for abuse liability","volume":"93","author":"Levinstein","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41398-024-02796-0","article-title":"The endogenous opioid system in the medial prefrontal cortex mediates ketamine\u2019s antidepressant-like actions","volume":"14","author":"Jiang","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.20240378","article-title":"Redefining ketamine pharmacology for antidepressant action: Synergistic NMDA and opioid receptor interactions?","volume":"182","author":"Levinstein","year":"2025","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.11.021_bib33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: Structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2025.11.021_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0773.1995.tb01041.x","article-title":"Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors","volume":"77","author":"Hustveit","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/0028-3908(87)90084-0","article-title":"Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro","volume":"26","author":"Smith","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","article-title":"Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine","volume":"119","author":"Gupta","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.biopsych.2025.11.021_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.11.021_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3565(25)21501-4","article-title":"A novel phencyclidine analog interacts selectively with mu opioid receptors","volume":"230","author":"Itzhak","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2025.11.021_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"An update on community ketamine practices","volume":"179","author":"O\u2019Brien","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(97)00255-2","article-title":"Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex","volume":"759","author":"Lindefors","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib41","article-title":"Ketamine prescriptions increasing, especially for mental health treatment","author":"Bartelt","year":"2023","journal-title":"Cosmos Study: Epic Research"},{"key":"10.1016\/j.biopsych.2025.11.021_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","volume":"66","author":"Swainson","year":"2021","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2024.05.131","article-title":"At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data","volume":"361","author":"Mathai","year":"2024","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.021_bib46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.021_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clements","year":"1982","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2025.11.021_bib49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","article-title":"Population pharmacokinetics of esketamine nasal spray and its metabolite Noresketamine in healthy subjects and patients with treatment-resistant depression","volume":"60","author":"Perez-Ruixo","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.biopsych.2025.11.021_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","article-title":"Oral ketamine for the treatment of pain and treatment-resistant depression","volume":"208","author":"Schoevers","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.12264","article-title":"The absolute bioavailability of racemic ketamine from a novel sublingual formulation","volume":"77","author":"Rolan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib52","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","article-title":"Pharmacokinetic considerations in abuse liability evaluation","volume":"86","author":"Farr\u00e9","year":"1991","journal-title":"Br J Addict"},{"key":"10.1016\/j.biopsych.2025.11.021_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-010-2062-x","article-title":"Ketamine self-administration in the rat: Evidence for a critical role of setting","volume":"214","author":"De Luca","year":"2011","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.biopsych.2025.11.021_bib54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","article-title":"Dual action of ketamine confines addiction liability","volume":"608","author":"Simmler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.11.021_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-3565(25)31050-5","article-title":"Ketamine self-administration by the rhesus monkey","volume":"203","author":"Moreton","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2025.11.021_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib57","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.biopsych.2025.11.021_bib58","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2025.11.021_bib59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.apha.2020.04.005","article-title":"The role of eEF2 kinase in the rapid antidepressant actions of ketamine","volume":"89","author":"Suzuki","year":"2020","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","article-title":"Therapeutic mechanisms of psychedelics and entactogens","volume":"49","author":"Heifets","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FBP.0b013e3282fe88a0","article-title":"Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats","volume":"19","author":"Zhai","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib62","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1111\/bph.70018","article-title":"(2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement in mice","volume":"182","author":"Michael","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib63","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1038\/s41467-019-13162-w","article-title":"Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories","volume":"10","author":"Das","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2025.11.021_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116513","article-title":"Can ketamine and other glutamate receptor modulators be considered entactogens?","volume":"349","author":"Hu","year":"2025","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib65","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/brainsci9040076","article-title":"Positive and negative emotion regulation in adolescence: Links to anxiety and depression","volume":"9","author":"Young","year":"2019","journal-title":"Brain Sci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib68","series-title":"Tasman\u2019s Psychiatry","first-page":"725","article-title":"Neurobiology of addiction","author":"Koob","year":"2024"},{"key":"10.1016\/j.biopsych.2025.11.021_bib69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YCO.0b013e3282f32408","article-title":"Major depression and comorbid substance use disorders","volume":"21","author":"Davis","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.addbeh.2018.11.008","article-title":"Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances","volume":"90","author":"Andersson","year":"2019","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2025.11.021_bib71","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib72","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib73","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00737-021-01185-6","article-title":"Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: Findings from short-term randomized, controlled trials","volume":"25","author":"Jones","year":"2022","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.biopsych.2025.11.021_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172927","article-title":"R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1","volume":"194","author":"Witkin","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.11.021_bib76","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s11064-004-6884-y","article-title":"NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats","volume":"29","author":"Ji","year":"2004","journal-title":"Neurochem Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib77","first-page":"33","article-title":"Interactions of ketamine, naloxone and morphine in the rat","volume":"39","author":"Fidecka","year":"1987","journal-title":"Pol J Pharmacol Pharm"},{"key":"10.1016\/j.biopsych.2025.11.021_bib78","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0091-3057(92)90181-E","article-title":"Effects of MK 801 on morphine physical dependence: Attenuation and intensification","volume":"43","author":"Koyuncuo\u011flu","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2025.11.021_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/ADM.0000000000000929","article-title":"Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use","volume":"16","author":"Hailozian","year":"2022","journal-title":"J Addict Med"},{"key":"10.1016\/j.biopsych.2025.11.021_bib80","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/00952990.2025.2541212","article-title":"Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression","volume":"51","author":"Manza","year":"2025","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.biopsych.2025.11.021_bib81","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/ph16040568","article-title":"Effect of ketamine on sleep in treatment-resistant depression: A systematic review","volume":"16","author":"Kwa\u015bny","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.biopsych.2025.11.021_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2020.03.048","article-title":"Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: A preliminary study","volume":"271","author":"Liu","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.021_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13400","article-title":"Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?","volume":"31","author":"Rodrigues","year":"2022","journal-title":"J Sleep Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-024-02956-2","article-title":"Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression","volume":"14","author":"Ballard","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib85","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4088\/JCP.15m10440","article-title":"Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder","volume":"78","author":"Vande Voort","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib86","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1037\/pha0000477","article-title":"Sleep disturbance as a therapeutic target to improve opioid use disorder treatment","volume":"30","author":"Huhn","year":"2022","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/wps.20306","article-title":"Treatment engagement of individuals experiencing mental illness: Review and update","volume":"15","author":"Dixon","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib88","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/npp.2017.19","article-title":"Prophylactic ketamine attenuates learned fear","volume":"42","author":"McGowan","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib89","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","article-title":"Ketamine as a prophylactic against stress-induced depressive-like behavior","volume":"79","author":"Brachman","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2019.112238","article-title":"Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors","volume":"378","author":"Mastrodonato","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ijnp\/pyac020","article-title":"Prophylactic (R,S)-ketamine is effective against stress-induced behaviors in adolescent but not aged mice","volume":"25","author":"Mastrodonato","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib92","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib93","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.biopsych.2018.02.011","article-title":"Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior","volume":"84","author":"Mastrodonato","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib94","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.biopsych.2024.09.024","article-title":"Prophylactic (R,S)-ketamine and (2S,6S)-hydroxynorketamine decrease fear expression by differentially modulating fear neural ensembles","volume":"97","author":"Mastrodonato","year":"2025","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib95","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopsych.2025.07.004","article-title":"Mu opioid receptor activation is required for NMDA receptor antagonist effects on stress-induced maladaptive behavior","volume":"99","author":"Langreck","year":"2026","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib96","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/npp.2013.231","article-title":"Dysregulation of dopamine and glutamate release in the prefrontal cortex and nucleus accumbens following methamphetamine self-administration and during reinstatement in rats","volume":"39","author":"Parsegian","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib97","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fncel.2015.00025","article-title":"Modulation of the glutamatergic transmission by dopamine: A focus on Parkinson, Huntington and Addiction diseases","volume":"9","author":"Gardoni","year":"2015","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib98","article-title":"Differential profiles of cognitive and behavioral inflexibility in addictive disorders","volume":"58","author":"Lim","year":"2024","journal-title":"Curr Opin Behav Sci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib99","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuroscience.2017.01.017","article-title":"Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex","volume":"346","author":"Jett","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2025.11.021_bib100","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.biopsych.2010.09.033","article-title":"Contributions of striatal dopamine signaling to the modulation of cognitive flexibility","volume":"69","author":"Darvas","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib101","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","article-title":"The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?","volume":"190","author":"Abdallah","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2025.11.021_bib102","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0269881114568041","article-title":"Neural correlates of change in major depressive disorder anhedonia following open-label ketamine","volume":"29","author":"Lally","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib104","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jad.2017.09.008","article-title":"Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study","volume":"225","author":"Chen","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2025.11.021_bib105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.biopsych.2014.06.024","article-title":"In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5","volume":"77","author":"DeLorenzo","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106279","article-title":"Ketamine metabolite alleviates morphine withdrawal-induced anxiety via modulating nucleus accumbens parvalbumin neurons in male mice","volume":"186","author":"Chen","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.biopsych.2025.11.021_bib107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.biopsych.2025.11.021_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112629","article-title":"Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review","volume":"392","author":"Grabski","year":"2020","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2025.11.021_bib109","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","article-title":"Therapeutic infusions of ketamine: Do the psychoactive effects matter?","volume":"136","author":"Dakwar","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2025.11.021_bib111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/0269881120970879","article-title":"Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial","volume":"35","author":"Rothberg","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib112","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib113","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnbeh.2020.00075","article-title":"Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in mice","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0024-3205(00)00639-1","article-title":"Effects of the non-competitive NMDA receptor antagonist ketamine on morphine-induced place preference in mice","volume":"67","author":"Suzuki","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2025.11.021_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110987","article-title":"The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement","volume":"253","author":"Drinkuth","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2025.11.021_bib117","article-title":"Selective transcriptomic recovery by (2R,6R)-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers","author":"Onisiforou","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopsych.2025.11.021_bib118","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10826084.2025.2497950","article-title":"Recreational ketamine use among individuals with opioid use disorder: Demographics, motivations, and polysubstance use","volume":"60","author":"Chandler","year":"2025","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.biopsych.2025.11.021_bib119","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12888-022-04175-9","article-title":"Treatment retention in opioid agonist therapy: Comparison of methadone versus buprenorphine\/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province","volume":"22","author":"Sadek","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2019.02.003","article-title":"Ketamine normalizes binge drinking-induced defects in glutamatergic synaptic transmission and ethanol drinking behavior in female but not male mice","volume":"149","author":"Crowley","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2025.11.021_bib121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.alcohol.2021.09.004","article-title":"Effect of ketamine on binge drinking patterns in crossed high alcohol-preferring (cHAP) mice","volume":"97","author":"Ardinger","year":"2021","journal-title":"Alcohol"},{"key":"10.1016\/j.biopsych.2025.11.021_bib122","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of Combined naltrexone and ketamine with Depressive Symptoms in a Case series of Patients with Depression and Alcohol Use Disorder","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2025.11.021_bib123","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2016.39","article-title":"Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial","volume":"22","author":"Dakwar","year":"2017","journal-title":"Mol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325016695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322325016695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:20:26Z","timestamp":1783502426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322325016695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0006322325016695"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.11.021","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2025.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}